Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to:
- Assess overall radiographic response rate (ORR)
- Assess progression-free survival (PFS)
- Test the safety and tolerability of Pembrolizumab in combination with lenvatinib
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute